Market Overview

Morning Market Losers

Related RIGL
Rigel Initiates Phase 3 Studies Of Fostamatinib In ITP
Corporate Events for the Week of Jun. 2nd, 2014
Related HRG
Will Central Garden Accept Harbinger's Acquisition Offer? - Analyst Blog
Benzinga's M&A Chatter for Monday June 23, 2014
Harbinger Offers $750M in Cash for Central Garden & Pet (Fox Business)

Rigel Pharmaceuticals (NASDAQ: RIGL) shares dipped 29.66% to $5.93 at 10:00 am. Rigel Pharmaceuticals' trailing-twelve-month ROE is -45.82%.

Harbinger Group (NYSE: HRG) shares lost 25.44% to $7.62. Harbinger Group announced a secondary public offering of shares of its common stock by selling shareholders.

Iridium Communications (NASDAQ: IRDMW) fell 20% to $0.88. Iridium Communications' 52-week trading range is $0.59-$2.97.

CounterPath (NASDAQ: CPAH) dropped 12.50% to $1.75. CounterPath posted a Q2 net loss of $0.3 million.

Posted-In: Morning Market LosersNews Movers & Shakers Intraday Update Markets

 

Most Popular

Related Articles (HRG + CPAH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free